These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 25097080)

  • 1. Editorial commentary: zoster vaccine in immunocompromised patients: time to reconsider current recommendations.
    Oxman MN; Schmader KE
    Clin Infect Dis; 2014 Oct; 59(7):920-2. PubMed ID: 25097080
    [No Abstract]   [Full Text] [Related]  

  • 2. Vaccination against zoster remains effective in older adults who later undergo chemotherapy.
    Tseng HF; Tartof S; Harpaz R; Luo Y; Sy LS; Hetcher RC; Jacobsen SJ
    Clin Infect Dis; 2014 Oct; 59(7):913-9. PubMed ID: 25097079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Varicella and herpes zoster vaccines: WHO position paper, June 2014.
    Wkly Epidemiol Rec; 2014 Jun; 89(25):265-87. PubMed ID: 24983077
    [No Abstract]   [Full Text] [Related]  

  • 4. Progress in VZV vaccination? Some concerns.
    Doerr HW
    Med Microbiol Immunol; 2013 Aug; 202(4):257-8. PubMed ID: 23649706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Varicella zoster virus redux.
    Gelb LD
    Herpes; 2009 Jan; 15(3):62-3. PubMed ID: 19306605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Varicella-zoster vaccine.
    Senanayake SN
    N Engl J Med; 2007 Jul; 357(1):89-90. PubMed ID: 17615639
    [No Abstract]   [Full Text] [Related]  

  • 7. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Harpaz R; Ortega-Sanchez IR; Seward JF;
    MMWR Recomm Rep; 2008 Jun; 57(RR-5):1-30; quiz CE2-4. PubMed ID: 18528318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccination against herpes zoster in developed countries: state of the evidence.
    Drolet M; Oxman MN; Levin MJ; Schmader KE; Johnson RW; Patrick D; Mansi JA; Brisson M
    Hum Vaccin Immunother; 2013 May; 9(5):1177-84. PubMed ID: 23324598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modeling the impact of combined vaccination programs against varicella and herpes zoster in Norway.
    Marchetti S; Guzzetta G; Flem E; Mirinaviciute G; Scalia Tomba G; Manfredi P
    Vaccine; 2018 Feb; 36(8):1116-1125. PubMed ID: 29366704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 70-year-old woman with shingles: review of herpes zoster.
    Whitley RJ
    JAMA; 2009 Jul; 302(1):73-80. PubMed ID: 19491172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current and future effects of varicella and herpes zoster vaccination in Germany - Insights from a mathematical model in a country with universal varicella vaccination.
    Horn J; Karch A; Damm O; Kretzschmar ME; Siedler A; Ultsch B; Weidemann F; Wichmann O; Hengel H; Greiner W; Mikolajczyk RT
    Hum Vaccin Immunother; 2016 Jul; 12(7):1766-76. PubMed ID: 26835890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Practical points for applying herpes zoster vaccine recommendations.
    Brogie JD; Rumph JH; Chaplin MD; Drake N; Hodge BK; Owens RE
    Nurse Pract; 2019 Sep; 44(9):43-47. PubMed ID: 31436592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Universal varicella vaccination reduced the incidence of herpes zoster in vaccine recipients 1 to 4 years of age.
    Toyama N; ; Shiraki K;
    J Dermatol Sci; 2018 Dec; 92(3):284-286. PubMed ID: 30551916
    [No Abstract]   [Full Text] [Related]  

  • 14. [Immunization of adults against varicella and herpes zoster].
    Hanslik T; Blanchon T; Alvarez FP
    Rev Med Interne; 2007 Mar; 28(3):166-72. PubMed ID: 17270316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a two-arm, randomised, double-blind, phase 3 trial.
    Mullane KM; Morrison VA; Camacho LH; Arvin A; McNeil SA; Durrand J; Campbell B; Su SC; Chan ISF; Parrino J; Kaplan SS; Popmihajlov Z; Annunziato PW;
    Lancet Infect Dis; 2019 Sep; 19(9):1001-1012. PubMed ID: 31399378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zoster vaccine: current status and future prospects.
    Oxman MN
    Clin Infect Dis; 2010 Jul; 51(2):197-213. PubMed ID: 20550454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Chickenpox and shingles: one virus, two diseases and current vaccination recommendations in Switzerland].
    Eckert N; Masserey Spicher V
    Ther Umsch; 2016; 73(5):247-52. PubMed ID: 27268447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity, reactogenicity and safety of 2 doses of an adjuvanted herpes zoster subunit vaccine administered 2, 6 or 12 months apart in older adults: Results of a phase III, randomized, open-label, multicenter study.
    Lal H; Poder A; Campora L; Geeraerts B; Oostvogels L; Vanden Abeele C; Heineman TC
    Vaccine; 2018 Jan; 36(1):148-154. PubMed ID: 29174683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Herpes zoster vaccine effectiveness and manifestations of herpes zoster and associated pain by vaccination status.
    Marin M; Yawn BP; Hales CM; Wollan PC; Bialek SR; Zhang J; Kurland MJ; Harpaz R
    Hum Vaccin Immunother; 2015; 11(5):1157-64. PubMed ID: 25806911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Herpes zoster vaccination in people aged 50-59 years.
    Li HT; Lu S; Liu JM
    Clin Infect Dis; 2012 Apr; 54(7):929-30. PubMed ID: 22291102
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.